Hydroxychloroquine in the treatment of COVID-19 disease: a systematic review and meta-analysis by Manzo Toledo, Amahirany et al.
Manzo-Toledo, et al. | Hydroxychloroquine for COVID-19 1
Medical Journal of Indonesia
Hydroxychloroquine in the treatment of COVID-19 disease: a systematic review and 
meta-analysis




BACKGROUND Given the urgency of finding a specific treatment for coronavirus 
disease 2019 (COVID-19), several approaches have been carried out, including the 
use of chloroquine (CQ) and hydroxychloroquine (HCQ). This study was aimed to 
systematically evaluate the available evidence on the effectiveness of HCQ in the 
treatment of COVID-19 disease.
METHODS We searched 3 databases (PubMed, Google Scholar, and ClinicalTrials) 
until May 31, 2020 for clinical studies in patients diagnosed with COVID-19 comparing 
conventional treatment with and without HCQ combined with or without azithromycin. 
The risk of bias assessment and quality evaluation was carried out according to the 
Cochrane recommendations.
RESULTS 5 articles (1 randomized clinical trial [RCT], 1 non-RCT, and 3 cohort studies) 
were included. The main outcome measure in 2 articles was the virological conversion 
determined by reverse transcription-polymerase chain reaction; however, the findings 
of both studies were contrary. The main objective of the other studies was to determine 
the effects of HCQ on COVID-19 mortality, and the studies showed similar results. 
In general, the studies showed methodological limitations, risk of bias, and variable 
quality. A meta-analysis from 2,041 patients showed the odds ratio of mortality for 
patients having HCQ and standard care was 1.38 (95% CI 0.93–2.04).
CONCLUSIONS Considering the limited data available and the very low-to-moderate 
quality of the studies included in this systematic review, the evidence suggests that the 
HCQ administration does not decrease the risk of death from COVID-19.
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At present, there is no specific treatment for 
coronavirus disease 2019 (COVID-19), and given the 
urgency of finding specific forms of treatment, several 
approaches have been carried out, including the use of 
chloroquine (CQ) and hydroxychloroquine (HCQ). CQ is 
an aminoquinoline with an antimalarial effect, from which 
its hydroxyl analog, HCQ, is derived. The latter has shown 
a better tolerability and a higher clinical safety profile 
of HCQ than that of CQ during long-term use, allowing 
a higher daily dose, having fewer pharmacological 
interactions,¹ and cost less. Likewise, in vitro and in vivo 
studies showed that HCQ had direct antiviral effects, 
which resulted from inhibition of the pH-dependent 
step of the replication of various viruses; inhibition of 
lysosomal activity in antigen-presenting cells, as well as 
immunomodulatory capacity. Thus, this drug has been 
shown to have anti-severe acute respiratory syndrome 
coronavirus activity, in vitro and in vivo.² 
Copyright @ 2021 Authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://
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However, although these experimental findings 
might support the possibility of use in humans, 
clinical data appeared to be conflicting and need 
to be interpreted with caution. Thus, it is crucial 
to conduct and analyze the literature about HCQ 
as a treatment for COVID-19. This study was aimed 
to systematically evaluate the available evidence 
on the effect of HCQ in the treatment of COVID-19 
disease.
METHODS
This systematic review is based on the preferred 
reporting item for systematic review and meta-analysis 
(PRISMA) and Cochrane³ guidelines.
Search strategy
The eligibility criteria, keywords, and algorithms 
used for search strategy are shown in Table 1. The 
search included all studies published until May 31, 
2020.
Selection of studies and data extraction
The process of selecting studies was carried out by 
two reviewers (AMT and LAF) independently, through 
the application of the eligibility criteria. A third reviewer 
(HMZ) resolved disagreements. Decisions about 
excluded studies were recorded with the reasons 
justifying their exclusion.
A standardized Microsoft Excel worksheet was 
prepared for the registration of the relevant data of all 
the studies included in the systematic review, such as 
participant demographics and baseline characteristics, 
the dosage, and frequency of administration of the 
drugs, statistical analysis, and primary outcome.
The study researchers were contacted for missing 
data or additional details via email. The data were 
recorded and processed in the Review Manager 5.4 
program.
Assessment of risk of bias
Two independent reviewers (RTR and LAAP) were 
responsible for the risk of bias assessment. The tools 
Strategy Description
Population Patients diagnosed with COVID-19
Intervention Hydroxychloroquine (HCQ) with or without azithromycin (AZI)
Comparator Placebo or symptomatic or conventional treatment
Outcomes Symptom relief, patient recovery, or seronegative or virological clearance or clinical cure
Study design Clinical trials, observational
Eligibility criteria
Studies involving adults and children with confirmation of the diagnosis for COVID-19 infection. In these 
studies, the intervention was with HCQ alone or in combination with AZI and the control group was without 
HCQ or with the administration of a placebo. Taking into account that the purpose of this review was to 
analyze the reported evidence that has a minimum quality, only original articles from randomized, non-
randomized, and observational clinical studies, peer-reviewed, and accepted for publication
Restrictions
English and Spanish language. Peer-reviewed articles. Database of U.S. National Institutes of Health’s 
National Library of Medicine (PubMed) or Scientific Electronic Library Online (Scielo)
Electronic database Medline/PubMed, Google Scholar, and ClinicalTrials.gov
Focused question What is the effect of HCQ as a medication for the specific treatment against COVID-19?
PubMed
(“COVID-19”[Supplementary Concept] OR “COVID-19”[All Fields] OR “covid19”[All Fields]) AND 
“treatment”[All Fields] AND (“hydroxychloroquine”[MeSH Terms] OR “hydroxychloroquine”[All Fields] OR 
“HCQ”[All Fields]) AND (“outcome”[All Fields] OR “recovery”[All Fields]) AND (“clinical trial”[All Fields] OR 
“clinical trials as topic”[MeSH Terms] OR “clinical trials”[All Fields])
Google Scholar “COVID-19”+”treatment”+”hydroxychloroquine”+(“outcome” or “recovery”)+”clinical trial”
ClinicalTrials.gov
COVID -19 OR SARS-COV-2 | treatment | hydroxychloroquine | recovery OR outcome | Filters: Completed 
Studies | Results
Table 1. Search strategy
COVID-19=coronavirus disease 2019; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2
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such as the Cochrane for assessing the risk of bias in 
randomized trials (RoB-2, Excel template with macros, 
online version)⁴ and the risk of bias in non-randomized 
studies - of interventions (ROBINS-I) for observational 
studies, were used.⁵
Quality assessment
The quality of each study was performed 
considering the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) 
criteria.⁶
Strategy for data synthesis
The qualitative and quantitative synthesis from 
the data of the included articles were performed. The 
heterogeneity between the measured effects from the 
studies was evaluated. The data were grouped according 
to a viral clearance and mortality. For the meta-analysis, 
the information collected from the selected studies were 
carefully analyzed to determine whether the studies 
can be grouped; however, studies that had a high risk 
of bias were not considered. Odds ratios were used 
from the individual studies and these were combined 
using a random-effects meta-analysis. Moreover, 95% 
confidence intervals (CI) and two-sided values were 
calculated. The heterogeneity between the studies in 
terms of measures of effect was evaluated using the I² 
statistic and was considered an I² value greater than 50% 
as being indicative of substantial heterogeneity.
RESULTS
Figure 1 shows the flow diagram of searching 
strategy. Of the five studies included in this systematic 
review, one randomized clinical trial (RCT), one non-
RCT, and three cohort studies were found. The results 
of these studies added up to a total of 2,173 participants, 
of whom 1,207 patients were treated with HCQ and 966 
patients were controls. The characteristics and results 
of the included studies can be seen in detail in Table 
2. The risk of bias in the randomized clinical study was 
high (Figure 2a). In the observational studies, Gautret's 
study⁷ had a critical risk of bias, while the other three 
studies had a low risk of bias (Figure 2b). The quality 
assessment of the studies included in the systematic 
review is shown in Table 3.
Gautret et al⁷ carried out a study coordinated 
by the Institute of the University Hospital of 
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systematic review
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Mediterranée Infection in Marseille where they 
proposed a treatment with HCQ. Nevertheless, several 
points in the design of this study should be noted. The 
participants in the control group were not all taken 
from the same hospital in which the patients in the 
experimental group were treated; also, the controls 
in the center of Marseille were those patients who 
refused to receive the treatment or met any of the 
exclusion criteria. On the other hand, the population 
base from which the participants were taken had 
a significant difference in the severity between the 
patients treated and not treated with HCQ. Moreover, 
the patients in the experimental group were older than 
those in the control group. The greatest risk of bias in 
this study was due to the lack of randomization in the 
intervention and the lack of blinding in all the people 
who participated in the study. The clinical condition 
of the participants in this study was categorized 
into: 1) asymptomatic; 2) upper respiratory tract 
infection; and 3) lower respiratory tract infection. The 
results did not show the raw data stratified by clinical 
condition; however, it was reported that the effect 
of the drug was greater in those with clinical signs of 
both upper and lower respiratory infection compared 
to asymptomatic patients (p<0.05). In principle, it is 
unusual for asymptomatic patients to be hospitalized, 
suggesting doubts about whether there was another 
reason to be hospitalized. Other doubtful aspects of 
this study arose from the insufficient follow-up period 
and incomplete viral load determinations using reverse 
transcription-polymerase chain reaction, of which the 
results showed that only 2 of 16 patients had a negative 
seroconversion on day-6 without mentioning that, in 5 
of the 16 patients, the viral load determination was not 
performed. Finally, in this study, the secondary results 
were not reported, which raises more doubts about 
the reliability of this study. For the above reasons, the 
quality was very low due to the high risk of bias, as well 
as its inconsistency and imprecision.
Tang et al⁸ carried out a randomized study where 
they reported as a primary result that the overall 
probability of negative conversion at 28 days after the 
intervention, no statistical difference between groups 
was found. Also, no clinical improvement results 
were presented, since, within the study population, 
disease severity was heterogeneous. Besides, during 
the trial, they included the probability of symptom 
relief (resolution of fever, cough, sore throat, sputum 
production, and shortness of breath) as a secondary 
outcome, which was similar in patients assigned to 
the standard care with HCQ and without HCQ. It is 
noteworthy that not all secondary outcomes were 
recorded in the trial although they were included 
in the protocol. On the other hand, the dose of HCQ 
was adjusted in the patients when adverse events 




























































































































































































































































































































































































































































































































































































































Figure 2. Risk of bias for individual studies from (a) risk of bias in randomized trials (RoB-2) assessment and (b) the risk of bias in 













































































































































Unique ID Study ID Experimental Comparator Outcome










studies Unique ID Study ID OutcomeComparatorExperimental
C1 Gautret, 2020 Clinical outcomeNo hydroxychloroquineHydroxychloroquine
(with or without AZI)
C2 Mahevas, 2020 Survival rateNo hydroxychloroquineHydroxychloroquine




C4 Geleris, 2020 Mortality rateNo hydroxychloroquineHydroxychloroquine
(with or without AZI)
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the intervention was not the same for the members of 
the group with HCQ. The increased risk of study bias 
was due to the selection and randomization of the 
participants. In the study design, the intervention was 
planned to be assigned by intention to treat; however, 
this could not be achieved in all patients, as in the group 
receiving standard care plus HCQ, six of the participants 
did not receive any doses of HCQ (three withdrew 
consent and three refused to be treated with HCQ) and 
were assigned to the standard care group. Also, one 
participant in the standard care group received HCQ 
because he presented with a severe clinical picture and 
was assigned to the standard care group plus HCQ. In 
addition to this, the study design was an open-label, 
so no type of blinding was applied. This study showed 
a high risk of bias, inconsistency, indirect results, and 
imprecision. As a consequence, the article had a very 
low quality.
Mahévas et al⁹ carried out an observational 
study comparing HCQ as a treatment for survival of 
patients with COVID-19 without a transfer to hospital 
intensive care units, in the intervention group and in 
the control group (not HCQ). After the intervention, 
Cox proportional hazards showed any risk differences 
between groups. An important point was that not 
all patients in the treatment group received the 
intervention at the same time since only some patients 
received HCQ 48 hours after admission and others 
within 48 hours of admission, so they considered these 
variables when adjusting the model. This study showed 
a low risk of bias.
Rosenberg et al¹⁰ conducted a retrospective cohort 
study, describing the association between HCQ with 
or without azithromycin (AZI) and clinical outcomes 
among hospitalized patients diagnosed with COVID-19. 
The result did not find that treatment with HCQ or AZI 
or in combination was different from not receiving any 
of the two drugs. The cohort consisted of a random 
sample of all the patients in 25 New York State hospitals, 
either one or both of the two experimental drugs were 
administered at the discretion of the treating physicians, 
but the assignation of the interventions occurred more 
frequently if the patients were sicker at the admission 
time, had comorbidities, or were elderly, which indicates 
that the baseline status was not homogeneous within 
groups. It should be noted that adverse effects, such as 
arrhythmias and cardiac arrest, could potentially appear 
before the initiation of the medication. Therefore, the 
onset of these events should be examined in relation to 
the time of administration of the medication. This study 
had a low risk of bias.
Geleris et al¹¹ conducted an observational study, 
in which there was no significant association between 
HCQ use and intubation or death. This study reported 
limitations during the collection of clinical information 
from the population. There could be missing data for 
some variables and the possibility of inaccuracies in 
electronic records, such as the lack of documentation 
on smoking and pre-existing disease in some patients. 
It should be mentioned that patients in the cohort of 
this study were paired by the administration of AZI, 
tocilizumab, and remdesivir in some of the participants 
in the intervention group and the control group. This 
study had a low risk of bias, and the quality of the 
information for the mortality evaluation of these last 
articles was moderate due to the inconsistency, indirect 
results, and imprecision.
The results of the meta-analysis in the present 
review obtained of 2,041 events from the three studies 
suggested that mortality showed no differences 
between the patients who received HCQ and the 
controls, as seen in Figure 3. The funnel plot is not 
shown due to the small number of studies included in 
the meta-analysis.
DISCUSSION
Currently, despite the fact that there are no drugs 
approved by health organizations to treat COVID-19, 
health professionals have begun to recommend HCQ, 
Figure 3. Meta-analysis of mortality for coronavirus disease 2019 (COVID-19) using hydroxychloroquine (HCQ) as treatment
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albeit without scientific support.¹² In the present 
review, regarding the participants, the included 
studies were found with small sample sizes (Gautret 
et al,⁷ Tang et al,⁸ and Mahévas et al⁹), while only two 
studies had a sufficient number of participants to be 
considered an appropriate sample (Geleris et al¹¹ and 
Rosenberg et al¹⁰). On the other hand, the illness, 
age, and comorbidities in the participants exhibited 
great heterogeneity (Mahévas et al,⁹ Tang et al,⁸ and 
Rosenberg et al¹⁰).
Regarding the intervention, in two studies 
(Rosenberg et al¹⁰ and Geleris et al¹¹), the administration 
of HCQ was in variable doses, routes, and time 
intervals. In contrast, in the other three studies, fixed 
doses of the drug were administered (Gautret et al,⁷ 
Tang et al,⁸ and Mahévas et al⁹). However, it seems 
that the differences in dose between studies showed 
no changes in the efficacy of the HCQ, except in 
Gautret et al⁷ study, which was at risk of critical bias 
and whose results were not reliable. On the other 
hand, in all studies, the comparator was those patients 
who received standard care without HCQ.
The use of CQ/HCQ for the treatment of viral 
diseases is not a recent idea. The in vitro test results were 
promising; however, the experiments were performed 
under limited virus replication conditions.¹³ Later, in 
vivo experiments demonstrated that CQ did not show 
any positive effects against H3N2 influenza virus.¹⁴ In 
the same way, in vitro studies claimed that CQ showed 
an effective anti-hepatitis C virus effect due to the drug 
acts by targeting autophagic proteolysis. Likewise, 
HCQ also has been tested against the hepatitis C virus, 
reporting a promising antiviral action.¹⁵ In addition, the 
antiviral effect of CQ has already been tested against 
HIV. In vitro studies seemed to suggest that the drug 
had broad-spectrum anti-HIV activity; nevertheless, 
in the animal experiments and few clinical trials, CQ 
exhibited no clinical benefit.¹⁶⁻¹⁹
Regarding the outcome, in the present systematic 
review, a meta-analysis using survival data with a 
random-effects model was performed because we 
considered the assumption that the studies were 
not all estimating the same intervention effect 
and had heterogeneity. The Χ² statistic test shows 
homogeneity; however, the I² statistic indicates a 
moderate percentage of inconsistency; therefore, as 
Χ² is not a test with high sensitivity, it is possible that 
the test may not have sufficient statistical power to 
detect heterogeneity. The choice between a fixed-
effect and a random-effects meta-analysis should 
never be made on the basis of a specific cut point value 
from the statistical test for heterogeneity instead of 
the rationality from the causes of heterogeneity.²⁰ 
Additionally, there is a clinical heterogeneity across 
the studies. Mahévas et al⁹ used data collected from 
routine care to assess the effectiveness of HCQ in 
patients with the same clinical severity of the disease 
(that required oxygen), whereas Rosenberg et al¹⁰ 
and Geleris et al,¹¹ the illness severity was registered. 
Likewise, the dose of HCQ were different across the 
studies.
On the other hand, the validity of the cohort 
studies depends on the assumption that both 
groups are comparable with respect to other factors 
associated with the intervention or the outcome 
of interest. Therefore, in the survival analysis, the 
adjustment of the model is essential, considering the 
covariates, confounding variables, and the censored 
participants.²¹ Due to censoring, the Cox proportional 
hazards was suitable for data analysis to avoid bias 
due to missing data.²² In contrast, in the Gautret et 
al⁷ study, the follow-up time was insufficient and no 
such adjustment was carried out. Likewise, propensity 
score model matching is one of the strategies in the 
statistical analysis to reduce the possibility of section 
bias due to differences in the baseline characteristics 
of the participants. This pairing helps avoid attributing 
the differences in the results between the experimental 
and control groups to individual characteristics, which 
could have influenced the decision to administer 
HCQ to each participant, instead of showing real 
differences between the groups caused by the effect 
of the treatment itself. In all the observational studies 
included in the review, each multivariate multiple 
regression model was adjusted for the covariates, 
which was adequate. In these studies, similar results 
were found in the comparisons before adjusting the 
baseline characteristics, being a value close to 1 with a CI 
that includes the unit (one). In the Geleris et al¹¹ study,it 
was shown that without adjusting the participants' 
baseline characteristics, the effect on mortality from 
HCQ was overestimated. Raw data found a 2.37-
fold increased risk of dying with HCQ administration 
compared with those that no receive HCQ. In the 
Geleris et al¹¹ study,after adjusting the groups with 
the covariates and matching of the participants, the 
risk was 0.98, with no significant difference in the risk 
between the two groups.
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Regarding adverse effects, a single-arm 
observational study found within the results that the 
administration of HCQ produced adverse effects such 
as gastrointestinal or cutaneous symptoms, headache, 
insomnia, and transient blurred vision presented mild 
adverse events in 2.35% of the patients, while in 97.6% 
of the patients the HCQ was well tolerated. In all, 0.04% 
of patients experienced more serious side effects, such 
as corrected QT interval (QTc) prolongation.²³ One of 
the important findings within the study by Rosenberg 
et al¹⁰ were adverse effects such as cardiac arrest 
and electrocardiographic findings (arrhythmias or 
prolonged QT fraction) in patients who received HCQ 
plus AZI or HCQ alone; these results were associated 
with pre-existing conditions such as hypertension, 
obesity, diabetes, elevation of liver enzymes, and 
abnormal kidney function. The metabolism of HCQ 
should also be considered, suggesting that toxicity is 
related to drug adherence in tissues. An interesting 
finding among the adverse effects was blurred vision, 
which, although it was considered a mild adverse 
effect, may be an indication of eye damage since HCQ 
is known to induce retinopathy. It binds to the melanin 
of the epithelial layer of the retina, resulting in loss of 
vision. Wolfe and Marmor²⁴ conducted a study on retinal 
toxicity in patients with rheumatoid arthritis or systemic 
lupus erythematosus, who had been treated with 
HCQ; from a total of 3,995 patients, 6.5% discontinued 
treatment due to an eye pathology, of which 1.8% had 
retinal problems. The risk of toxicity was low in the first 
7 years of exposure and was approximately five times 
higher after that period. Overall, the incidence of HCQ 
side effects appears to be relatively small when used 
for short intervals of time.
Several clinical trials have been suspended because 
preliminary results indicated that this drug provided 
no additional benefit or harm that the placebo for 
hospitalized COVID-19 patients, which is in agreement 
with the findings of this review.²⁵ Also the Solidarity Trial 
results in HCQ arm was suspended with 954 patients. 
The death rate ratio for HCQ was relative risk = 1.19 
(95% CI 0.89–1.59, p = 0.23) and death/survival ratio for 
HCQ was 104/947 patients against its control (84/906) 
patients. In consequence, the evidence suggests that 
the HCQ is not a reliable treatment for COVID-19.²⁶
The results of the present meta-analysis are in 
contrast with the review performed by Meo et al²⁷ in 
which they reviewed in vitro studies, in vivo studies, 
original studies, clinical trials, and consensus reports, 
and concluded that CQ and HCQ could be useful 
against COVID-19. The potential deficiencies of this 
work are that there is no evidence that the PRISMA 
recommendations were followed, and the certainty 
of the evidence was considered the same for all types 
of study designs. Likewise, the risks of bias and quality 
assessment of the included studies were not carried 
out, and these are likely the reasons for the disparities 
in the results and conclusions reached. On the contrary, 
the present article performed a systematic review of 
the publications and included RCTs and observational 
studies. These methodological designs with patients 
showed more external validity and their results could 
be extrapolated to the clinical context. Additionally, 
most of these articles had a low risk of bias.
In contrast, a systematic review and meta-analysis 
made by Sarma et al,²⁸ who found the virological 
cure outcome from two studies included, a high 
percentage of variation across studies attributable to 
heterogeneity (I² = 73%). However, another issue in that 
analysis was identified. For all the previous reasons 
about the high risk of bias and low quality from the 
Gautret et al⁷ study, their data were not appropriate to 
include in the meta-analysis. On the other hand, one of 
the problems of including small studies was the random 
error attributable to an insufficient sample, where the 
results could be scattered around the real effect and 
that can lead to overestimating or underestimating the 
effect.²⁰ The two studies included in the meta-analysis 
had 57 and 40 participants, respectively. Besides, in 
such an analysis, a certain variation in the effect of 
the intervention is observed, and the inconsistency in 
the direction of the effect is particularly notable, so it 
can be misleading to quote an average value for the 
intervention effect.²⁹ As a result, the analysis of the 
numerical data was misinterpreted.
Also, in the review carried out by Shah et al³⁰ was 
reported the lack of robust evidence for HCQ and CQ 
as prophylactic drugs to prevent COVID-19. The main 
limitation was the design of the articles included in the 
review (three in vitro studies and two opinion articles), 
in consequence, they pointed out the need for data 
from RCTs to obtain reliable evidence. According 
to that, the use of HCQ is not recommendable as a 
prophylactic for COVID-19.
In conclusion, although it is essential to find a 
specific treatment for COVID-19 as soon as possible, 
shortcuts should not be taken in the methodological 
design to produce reliable data. Considering the 
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limited data available and the low-to-moderate quality 
of the included studies in this systematic review, the 
evidence suggests that the HCQ administration does 
not decrease the risk of death from COVID-19.
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